MTNB Matinas BioPharma Net earnings per share for the last 12 months

Public company logo of matinasbiopharma.com (MTNB)

Matinas BioPharma (MTNB) management strictly controls capital and transparently discloses the results of MAT2203 trials. The fundamental EPS TTM metric demonstrates financial stability, while the -18.06 mark indicates the current yield level. The team is developing LNC technologies through strategic alliances, while patent protection and strict FDA regulations create a robust barrier to entry for new players.

MTNB (Matinas BioPharma Holdings Inc.) Net earnings per share (EPS TTM) history from 07/04/2022 to 11/14/2026

Analytical breakdowns and data insights for company Matinas BioPharma (MTNB)

- stock price and consensus target price:
Stock Price Matinas BioPharma Holdings Inc.|MTNB - Average Forecast Price
- market capitalization data:
Market Valuation Matinas BioPharma Holdings|MTNB - Aggregate Business Value
- balance sheet net asset value indicators:
Book Value per Share Matinas BioPharma|MTNB - Book Capitalization|Market Capitalization to Book Value Ratio matinasbiopharma.com|MTNB - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Matinas BioPharma|MTNB - Long-Term Liabilities to Capital|Short-Term Debt to Equity matinasbiopharma.com|MTNB - Company Debts|Debts to Book Capitalization Matinas BioPharma|MTNB - Long-Term Debt Volume|Company Short-Term Debt Matinas BioPharma|Quick Liquidity matinasbiopharma.com
- net income and valuation multiples indicators:
MTNB - Net Income|Expected Profit Matinas BioPharma|MTNB - Price to Earnings Ratio|Forward P/E Multiple Matinas BioPharma|MTNB - PEG Multiple|Enterprise Value to EBITDA Ratio Matinas BioPharma Holdings|MTNB - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Matinas BioPharma|MTNB - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months matinasbiopharma.com|MTNB - Earnings per share growth this year|Earnings growth forecast for next year Matinas BioPharma
- sales and revenue data:
MTNB - Revenue and Sales Volume|Company Projected Revenue Matinas BioPharma Holdings, Inc.|MTNB - Price-to-Revenue Coefficient|Forward Price-to-Revenue Multiple Matinas BioPharma
Fundamental company valuation:Matinas BioPharma (MTNB)
Mass-produced product of Matinas BioPharma Holdings Inc.

It is critical for investors to identify an issuer's financial risks in a timely manner to protect their capital. The specifics of drug delivery platform development provide Matinas BioPharma (MTNB) with macro-resilience and independence from GDP cycles. The company's TTM net income per share reflects the total earnings distributed per common share over the year. Analyzing this metric allows for the tracking of margin compression amid expensive debt capital. A stable trend in this indicator confirms the fundamental reliability of the business.

Competitors of Matinas BioPharma

Ascendis - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Madrigal Pharma|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Inc|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (Crinetics Pharmaceuticals, Inc.)|Earnings per share for the last twelve months newamsterdampharma.com NAMS|Soleno Therapeutics Corp (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|SPRB: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months Galecto Corp|CTCX (Carmell Corp) - Net earnings per share for the last 12 months|Lumos Pharma Corp - Earnings per share for the trailing year|Net earnings per share for the last 12 months ONVO|Net earnings per one share for the last twelve months Radius Recycling, Inc. RDUS